Novavax NVAX
NASDAQ NVAX
$10.46 -0.14 (-1.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Novavax (NVAX) Selling, General & Administrative (2010 - 2026)

Updated

Novavax (NVAX) recorded Selling, General & Administrative of $26.67 million in Q2 2026, down 38.9% from $43.61 million a year earlier and down 7.3% from the prior quarter.

Analysis

Novavax (NVAX) Selling, General & Administrative (2010 - 2026) Analysis & Trends

On a TTM basis, Novavax's Selling, General & Administrative came in at $121.22 million as of Jun 30, 2026, down 49.7% year-over-year; for FY2025, it came in at $157.48 million, down 53.3% from FY2024.

  • Annual Selling, General & Administrative has declined for three straight years, though with a five-year compound annual growth rate of 1.6% (FY2020 to FY2025).
  • Across earlier years, Selling, General & Administrative came in at $337.19 million in FY2024 (-28.1%), $468.95 million in FY2023 (-4.0%), $488.69 million in FY2022 (+63.8%) and $298.36 million in FY2021 (+105.4%).
  • The Q2 2026 figure is the lowest quarterly Selling, General & Administrative since Q2 2020.
  • On a year-over-year basis, Selling, General & Administrative has declined for eight consecutive quarters, with an average decline of 47.0% over the last eight quarters.
  • Peak year-over-year performance for Selling, General & Administrative in the last five years was growth of 92.0% in Q4 2022, against a decline of 56.9% in Q2 2025 at the low end.
  • Per Business Quant, the preceding three quarters came in at $28.78 million (Q1 2026), $34.12 million (Q4 2025) and $31.66 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 3.43 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 6.43 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.63 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 2.90 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -3.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -5.65 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 1.75 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 1.92 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 3.41 Bn
10 Novavax 1.72 Bn -1.28 Bn 42.45 Mn 26.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 26.67 Mn
Mar 31, 2026 28.78 Mn
Dec 31, 2025 34.12 Mn
Sep 30, 2025 31.66 Mn
Jun 30, 2025 43.61 Mn
Mar 31, 2025 48.09 Mn
Dec 31, 2024 78.34 Mn
Sep 30, 2024 70.75 Mn
Jun 30, 2024 101.30 Mn
Mar 31, 2024 86.80 Mn
Dec 31, 2023 155.24 Mn
Sep 30, 2023 107.46 Mn
Jun 30, 2023 93.72 Mn
Mar 31, 2023 112.53 Mn
Dec 31, 2022 161.66 Mn
Sep 30, 2022 122.88 Mn
Jun 30, 2022 108.16 Mn
Mar 31, 2022 95.99 Mn
Dec 31, 2021 84.21 Mn
Sep 30, 2021 77.79 Mn
API Access

Novavax Selling, General & Administrative API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=NVAX&period=max&api_key=YOUR_API_KEY